Competitors Bureau Statement Concerning Its Proactive Monitoring Of Probably Anticompetitive Patent Litigation Settlement Agreements Between Branded And Generic Drug Producers: Versionshistorik

Hoppa till navigering Hoppa till sök

Val av diff: markera i radioknappen för att jämföra sidversioner och tryck enter eller knappen längst ner.
Förklaring: (nuvarande) = skillnad mot senaste sidversion; (föregående) = skillnad mot föregående sidversion; m = mindre ändring.

    31 december 2022

    • nuvarandeföregående 13.4231 december 2022 kl. 13.42‎ Josie67Y61015175 diskussion bidrag‎ 5 333 byte +5 333‎ Skapade sidan med 'The Bureau’s Intellectual Property Enforcement Guidelines establish that patent litigation settlement agreements may be anticompetitive, corresponding to when payments (whether financial or non-monetary) are made to delay the entry of generic medicine into the market. GATINEAU, May 20, 2022— Promoting and defending competitors within the Canadian health care sector is a priority for the Competition Bureau. As a part of these efforts, the Bureau proactively displays p...'
Hämtad från "https://psalmerna.se/Wikiny/index.php?title=Competitors_Bureau_Statement_Concerning_Its_Proactive_Monitoring_Of_Probably_Anticompetitive_Patent_Litigation_Settlement_Agreements_Between_Branded_And_Generic_Drug_Producers"